#ADPKD
LightNews LightNews
asnpublications.bsky.social
The November issue of JASN is now available online! Topics covered include:
- SGLT2i in a Mouse Model of ANCA-Associated Vasculitis
- Pregnancy and CKD Progression in ADPKD
- and more
kidney.pub/JASN-1126
#ASNJASN
November 3, 2026 at 4:04 PM
asnpublications.bsky.social
New ASN Kidney Translation Podcast episode reviews 2 late-breaking clinical trials published simultaneously with #KidneyWk: empagliflozin in ADPKD and upacicalcet for secondary hyperparathyroidism in hemodialysis. kidney.pub/KTPOD102426
October 30, 2026 at 6:00 PM
shihcheng.bsky.social
Unveiling the structural basis of lipid-dependent allosteric gating in PC1-PC2 ion channels, crucial for ADPKD. Discover how PG and PA keep channels closed! PMID:42420301, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-75084-8 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Structural basis of lipid-dependent allosteric gating mechanisms for PC1-PC2 ion channel | Nature Communications
The polycystin complex, consisting of one polycystin-1 (PC1) and three polycystin-2 (PC2), forms a cation channel localized to the primary cilium and is critically involved in autosomal dominant polycystic kidney disease (ADPKD). This study reveals an allosteric gating mechanism of the PC1-PC2 channel modulated by specific membrane lipids. In typical membrane environments, phosphatidylglycerol (PG) and phosphatidic acid (PA) bind to the channel central pore, maintaining it in a closed state. Dissociation of these lipids transitions the channel to a pre-open state. The cilia-enriched oxysterol 7β,27-dihydroxycholesterol (7β,27-DHC) stabilizes the channel in a more open but still non-conductive conformation through an allosteric mechanism. Lipid-mediated regulation is coupled to large conformational rearrangements of the TOP and voltage-sensor-like domains (VSDs) of the third PC2 subunit, which eventually leads to pore opening. This lipid-dependent modulation is also obser
doi.org
November 3, 2026 at 2:00 PM
asnpublications.bsky.social
ADPKD is more than a cystic kidney disease. #Perspective in #ASNJASN highlights how metabolic and cardiovascular dysfunction may accelerate ADPKD progression, supporting a more holistic CKM approach to prevention, treatment, and patient care. #ADPKD kidney.pub/JASN1291 @cu-kidney.bsky.social
October 27, 2026 at 5:30 PM
newsen.bsky.social
Eloxx Pharmaceuticals Secures FDA Clearance for Exaluren in ADPKD, Paving the Way for Clinical Trials#United_States#ADPKD#Darlington#Eloxx_Pharmaceuticals#Exaluren
Eloxx Pharmaceuticals Secures FDA Clearance for Exaluren in ADPKD, Paving the Way for Clinical Trials
Eloxx Pharmaceuticals has received FDA clearance to proceed with clinical trials for Exaluren, a potential treatment for ADPKD. The Phase 2 trial will enroll about 60 patients, with results expected in 2029.
third-news.com
October 29, 2026 at 12:40 PM
nephrosage.bsky.social
Renal blood flow and progression to kidney failure in ADPKD
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
Renal blood flow and progression to kidney failure in ADPKD
ABSTRACTBackground. A decrease in renal blood flow (RBF) precedes estimated glomerular filtration rate (eGFR) decline among patients with autosomal dominan
academic.oup.com
October 29, 2026 at 4:31 PM
pkdresearch.bsky.social
Advancing ADPKD Research!

Dr. Stephen Seliger presented collaborative research on empagliflozin therapy in ADPKD at ASN Kidney Week 2026. Congratulations to Drs. Seliger and Chonchol!

Publication: pubmed.ncbi.nlm.nih.gov/42925875/

#ADPKD #KidneyResearch
October 27, 2026 at 5:10 PM
drachten.vacatureforum.nl.ap.brid.gy
Geneesmiddelenonderzoek GL0018-1737-GRQ (Vergoeding tot €4.284,-)
Bekijk hier de vacature: https://vacatures-drachten.nl/vacature/geneesmiddelenonderzoek-gl0018-1737-grq-vergoeding-tot-4-284/
#vacature #drachten #icon
Geneesmiddelenonderzoek GL0018-1737-GRQ (Vergoeding tot €4.284,-) - Vacatures Drachten
Jobid: 644360477105135591 (0.0648) Wat ga je doen? ICON zoekt deelnemers voor een geneesmiddelenonderzoek naar een nieuw middel voor nierziekten (ADPKD). Voor je deelname ontvang je een […]
vacatures-drachten.nl
November 3, 2026 at 12:36 AM
drachten.vacatureforum.nl.ap.brid.gy
Geneesmiddelenonderzoek GL-GRQ (Vergoeding tot €4.284,-)
Bekijk hier de vacature: https://vacatures-drachten.nl/vacature/geneesmiddelenonderzoek-gl-grq-vergoeding-tot-4-284/
#vacature #drachten #icon
Geneesmiddelenonderzoek GL-GRQ (Vergoeding tot €4.284,-) - Vacatures Drachten
Jobid: 3208650698 (0.2) Wat ga je doen? ICON zoekt deelnemers voor een geneesmiddelenonderzoek naar een nieuw middel voor nierziekten (ADPKD). Voor je deelname ontvang je een […]
vacatures-drachten.nl
November 3, 2026 at 12:31 AM
drachten.vacatureforum.nl.ap.brid.gy
Geneesmiddelenonderzoek GL0018-1737-GRQ (Vergoeding tot €4.284,-)
Bekijk hier de vacature: https://vacatures-drachten.nl/vacature/geneesmiddelenonderzoek-gl0018-1737-grq-vergoeding-tot-4-284-2/
#vacature #drachten #icon
Geneesmiddelenonderzoek GL0018-1737-GRQ (Vergoeding tot €4.284,-) - Vacatures Drachten
Jobid: 3414_1279825 (0.186) Wat ga je doen? ICON zoekt deelnemers voor een geneesmiddelenonderzoek naar een nieuw middel voor nierziekten (ADPKD). Voor je deelname ontvang je een […]
vacatures-drachten.nl
November 3, 2026 at 10:01 PM
pkdinternational.bsky.social
How can shared experiences shape better care for people living with PKD?

Explore the interactive report of PKD International’s Global Members Meeting in Leuven: 11 chapters sharing patient perspectives on care, research and life with PKD.

www.pkdinternational.org/news-and-eve...

#ADPKD #ARPKD
Leuven 2026: Research and Patient Voices
Research advances raise new choices for people living with PKD.
www.pkdinternational.org
October 29, 2026 at 8:48 AM
asnpublications.bsky.social
Our kidneys have their own “body clock.” A #basicresearch study in #ASNKidney360 suggests that in ADPKD, that clock may be disrupted as cysts grow. Researchers hope these findings could lead to new ways to protect kidney function in the future. kidney.pub/KID1347
October 27, 2026 at 3:32 PM
mahjoublab.bsky.social
Had a great time at #KidneyWeek, seeing old friends again and meeting new ones.
So happy to see that the American Society of Nephrology program had so many sessions on #ADPKD and other #cystic kidney diseases this year 🔥

And thanks again to #KidneyCure for the award and reception 🙏
October 26, 2026 at 4:54 PM
jmteakell.bsky.social
#ADPKD has unique considerations

#Kidneywk
October 24, 2026 at 11:21 PM
hswapnil.medsky.social
Another LBCT from today’s #KidneyWk

journals.lww.com/jasn/abstrac... in @asnpublications.bsky.social #JASN

ADPKD has been excluded from flozins trials (concern about cyst growth) - and this pilot trial does show that

VA by @edgarvlermamd.medsky.network
VA by Edgar
October 24, 2026 at 10:54 PM
jmteakell.bsky.social
Polycystic Kidney Disease and PD: Truth or Myth

Dr. Ankur Shah
#Kidneywk #ADPKD
October 24, 2026 at 11:18 PM
jmteakell.bsky.social
Patients with ADPKD are high utilizers of home dialysis and preemptive transplant.
#Kidneywk
October 24, 2026 at 11:23 PM
stocktitan.net
#ELOX Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation…

https://www.stocktitan.net/news/ELOX/eloxx-pharmaceuticals-announces-fda-clearance-of-investigational-new-hnw3zpuia1hg.html?utm_source=stocktitan-bluesky&utm_medium=social
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 29, 2026 at 12:00 PM
nkf-professionals.bsky.social
Where does genetics fit into your kidney care practice?

Explore established approaches, emerging research, and patient perspectives in the Genetics in Kidney Health Summit recordings.

Watch: vimeo.com/showcase/124...

#Nephrology #Genetics #Nephrology #ADPKD #APOL1 #Medical
2026 Genetics in Kidney Disease Summit on Vimeo
Join the web’s most supportive community of creators and get high-quality tools for hosting, sharing, and streaming videos in gorgeous HD with no ads.
vimeo.com
October 29, 2026 at 3:00 PM
nephjc.bsky.social
#kidneywk Day 3 of simultaneous publications covered by #nephjc

Until the next time 👋

✍️ @nephroseeker.medsky.social @dramiliflores.bsky.social @nephromommy-akshu.bsky.social @hswapnil.medsky.social

www.nephjc.com/news/denver-...
Kidney Week in Denver: Day 3 — NephJC
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
www.nephjc.com
October 25, 2026 at 2:17 PM
runningkidneys.bsky.social
🫘 Empagliflozin in ADPKD: A pilot RCT (JASN; n=50) showed good tolerability and an early eGFR dip followed by stabilization, but greater kidney volume increase vs placebo.

🔬 Larger trials needed.

🔗 www.ovid.com/jnls/jasn/fu...
Empagliflozin Therapy in Autosomal Dominant... : Journal of the American Society of Nephrology
Key PointsEmpagliflozin 25 mg once daily for 12 months was safe and well tolerated in adults with autosomal dominant polycystic kidney disease at...
www.ovid.com
October 27, 2026 at 5:02 PM
edgarvlermamd.medsky.network
Diagnosis of ADPKD remains radiological/ clinical in most cases
#Nephpearls #KidneyWk #NephSky

👉 pubmed.ncbi.nlm.nih.gov/40126492/
October 23, 2026 at 12:17 AM
ibressendorff.bsky.social
There’s also this one from a few years ago, in which TKV stabilised
www.kireports.org/article/S246...
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney dis...
www.kireports.org
October 24, 2026 at 11:19 PM
kireports.bsky.social
Randomized Controlled Trial of #Salt and #Amiloride on #Vascular #Stiffness in #ADPKD

#VisualAbstract by Edgar V. Lerma 🇵🇭

https://www.kireports.org/article/S2468-0249(26)03342-5/fulltext
October 23, 2026 at 1:00 AM